Leung MW, Bazelier MT, Souverein PC, Uitdehaag BM, Klungel OH, Leufkens HG, Pajouheshnia R. Mapping the risk of infections in patients with multiple sclerosis: a multi-database study in the United Kingdom clinical practice research datalink GOLD and aurum. Mult Scler. 2022 Oct;28(11):1808-18. doi: 10.1177/13524585221094218.
Cadigan RJ, Edwards TP, Lassiter D, Davis AM, Henderson GE. "Forward-Thinking" in U.S. biobanking. Genet Test Mol Biomark. 2017 Mar;21(3):148-54. doi: 10.1089/gtmb.2016.0393
Fernandez MM, Wang J, Ye X, Kwong WJ, Sherif B, Hogue S, Sherrill B. Systematic review and network meta-analysis of the relative efficacy and safety of edoxaban versus other nonvitamin K antagonist oral anticoagulants among patients with nonvalvular atrial fibrillation and CHADS2 score slanted greater than or equal to 2. SAGE Open Med. 2015 Dec. doi: 10.1177/2050312115613350
Meads DM, Doward LC, McKenna SP, Fisk J, Twiss J, Eckert B. The development and validation of the Unidimensional Fatigue Impact Scale (U-FIS). Mult Scler. 2009 Oct 1;15(10):1228-38. doi: 10.1177/1352458509106714
Miret M, Perez-Gutthann S, Gutierrez LP, Viglietta V, Musch B, Greenberg S. Evaluation of the long-term safety of Cladribine tablets: design of a prospective 8-year safety registry. Poster presented at the European Committee for Treatment and Research of Multiple Sclerosis (ECTRIMS); 2009. Dusseldorf, Germany. [abstract] Mult Scler. 2009 Sep 8; 15(Issue Suppl_9):S239. doi: 10.1177/1352458509106963
Doward LC, McKenna SP, Meads DM, Twiss J, Eckert BJ. The development of Patient Reported Outcome Indices for Multiple Sclerosis (PRIMUS). Mult Scler. 2009 Sep 1;15(9):1092-102.
Doward LC, McKenna SP, Meads DM, Twiss J, Hagell P, Oprandi N. Psychometric and scaling properties of the patient reported outcome indices for multiple sclerosis (PRIMUS). Mult Scler. 2007 Jun;13(Suppl 2):S219.
Doward LC, Meads DM, Fisk JD, McKenna SP, Eckert BJ. Derivation of a unidimensional scale from the fatigue impact scale. Mult Scler. 2006 Sep;12(Suppl 1):S1-S228.